We have located links that may give you full text access.
A Real-World Data Retrospective Cohort Study of Low Estrogen Receptor-Positive Early Breast Cancer: Natural History and Treatment Outcomes.
Purpose: Estrogen receptor-positive (ER+ ) breast cancer (BC) is a heterogeneous disease, and there is an ongoing debate regarding the optimal cut point for clinically relevant ER expression. We used a real-world database to assess the prognostic and predictive values of lower ER expression levels on treatment outcomes with endocrine therapy.
Methods: We used a nationwide electronic health record database. Descriptive statistics were used to evaluate the association between ER expression, tumor characteristics, and treatment patterns among patients with early-stage BC. We used Kaplan-Meier survival curves to estimate recurrence-free survival (RFS) and overall survival (OS). We assessed associations between an alternative ER expression-level cut point and clinical outcomes.
Results: Among 4697 patients with early-stage HER2-negative BC, 83 (2.04%) had ER+ -low BC (ER expression, 1-9.99%) and 36 (0.88%) had ER+ -intermediate BC (10-19.9%). ER+ -low tumors were associated with higher tumor grade, larger size, and higher axillary tumor burden than ER+ -high tumors (≥20% ER expression). African Americans had a higher prevalence of both triple-negative BC (TNBC) and ER+ -low BC than ER+ -high BC. Patients with ER+ -low and ER+ -intermediate tumors had survival outcomes similar to patients with TNBC and worse survival outcomes than patients with ER+ -high tumors ( P < 0.001). Tumors with <20% ER expression were associated with worse outcomes.
Conclusion: In our cohort, patients with BCs with ER expression levels <20% had poor clinical outcomes similar to those of patients with TNBC.
Methods: We used a nationwide electronic health record database. Descriptive statistics were used to evaluate the association between ER expression, tumor characteristics, and treatment patterns among patients with early-stage BC. We used Kaplan-Meier survival curves to estimate recurrence-free survival (RFS) and overall survival (OS). We assessed associations between an alternative ER expression-level cut point and clinical outcomes.
Results: Among 4697 patients with early-stage HER2-negative BC, 83 (2.04%) had ER+ -low BC (ER expression, 1-9.99%) and 36 (0.88%) had ER+ -intermediate BC (10-19.9%). ER+ -low tumors were associated with higher tumor grade, larger size, and higher axillary tumor burden than ER+ -high tumors (≥20% ER expression). African Americans had a higher prevalence of both triple-negative BC (TNBC) and ER+ -low BC than ER+ -high BC. Patients with ER+ -low and ER+ -intermediate tumors had survival outcomes similar to patients with TNBC and worse survival outcomes than patients with ER+ -high tumors ( P < 0.001). Tumors with <20% ER expression were associated with worse outcomes.
Conclusion: In our cohort, patients with BCs with ER expression levels <20% had poor clinical outcomes similar to those of patients with TNBC.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app